DOI:
10.1055/s-00000133
Gastroenterologie up2date
LinksClose Window
References
Yoo C, Hwang JY, Kim JE et al.
A randomised phase II study of modified FOLFIRI. 3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Br J Cancer 2009;
101: 1658-1663
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.